[go: up one dir, main page]

WO2006124544A3 - Use of tyrosine kinase inhibitors in the treatment of metabolic disorders - Google Patents

Use of tyrosine kinase inhibitors in the treatment of metabolic disorders Download PDF

Info

Publication number
WO2006124544A3
WO2006124544A3 PCT/US2006/018342 US2006018342W WO2006124544A3 WO 2006124544 A3 WO2006124544 A3 WO 2006124544A3 US 2006018342 W US2006018342 W US 2006018342W WO 2006124544 A3 WO2006124544 A3 WO 2006124544A3
Authority
WO
WIPO (PCT)
Prior art keywords
tyrosine kinase
kinase inhibitors
treatment
metabolic disorders
adipocyte
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/018342
Other languages
French (fr)
Other versions
WO2006124544A2 (en
Inventor
Jeffrey Porter
Thomas Edward Hughes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Novartis AG
Original Assignee
Novartis Pharma GmbH Austria
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma GmbH Austria, Novartis AG filed Critical Novartis Pharma GmbH Austria
Publication of WO2006124544A2 publication Critical patent/WO2006124544A2/en
Publication of WO2006124544A3 publication Critical patent/WO2006124544A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the use of c-Abl-, PDGF-R-, c-kit-, or ARG-tyrosine kinase inhibitors, or pharmaceutically acceptable salts thereof, for the treatment, amelioration, and diagnosis of disorders associated with aberrant expression of adipocyte-specific peptide hormone in a patient, e.g., metabolic disorders, e.g., type I diabetes or type II diabetes, and for the manufacture of pharmaceutical compositions for the treatment, amelioration, and diagnosis of disorders associated with aberrant expression of adipocyte-specific peptide hormone in a patient. Examples of c-Abl-, PDGF-R-, c-kit-, or ARG-tyrosine kinase inhibitors include Compound I and Compound II, and pharmaceutically acceptable salts thereof. The ability of the c-Abl-, PDGF-R-, c-kit-, or ARG-tyrosine kinase inhibitors, or pharmaceutically acceptable salts thereof, to treat metabolic disorders is based at least in part on their ability to bind adipocyte-specific peptide hormones such as adiponectin.
PCT/US2006/018342 2005-05-13 2006-05-11 Use of tyrosine kinase inhibitors in the treatment of metabolic disorders Ceased WO2006124544A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68071405P 2005-05-13 2005-05-13
US60/680,714 2005-05-13

Publications (2)

Publication Number Publication Date
WO2006124544A2 WO2006124544A2 (en) 2006-11-23
WO2006124544A3 true WO2006124544A3 (en) 2007-09-07

Family

ID=37431881

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/018342 Ceased WO2006124544A2 (en) 2005-05-13 2006-05-11 Use of tyrosine kinase inhibitors in the treatment of metabolic disorders

Country Status (1)

Country Link
WO (1) WO2006124544A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013510834A (en) 2009-11-16 2013-03-28 メリテク [1,5] -diazocine derivatives
IL234962A0 (en) * 2014-10-02 2015-01-29 Yeda Res & Dev Use of agents for treating fat-related disorders
CN116173023A (en) * 2022-09-09 2023-05-30 中南民族大学 New application of lenvatinib in preventing and treating type II diabetes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009367A2 (en) * 2003-07-17 2005-02-03 Ambit Biosciences Corporation Treatment of diseases with kinase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009367A2 (en) * 2003-07-17 2005-02-03 Ambit Biosciences Corporation Treatment of diseases with kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LASSILA M ET AL: "IMATINIB ATTENUATES DIABETES-ASSOCIATED ATHEROSCLEROSIS", ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, vol. 24, no. 5, May 2004 (2004-05-01), pages 935 - 942, XP008037837, ISSN: 1079-5642 *

Also Published As

Publication number Publication date
WO2006124544A2 (en) 2006-11-23

Similar Documents

Publication Publication Date Title
WO2006059108A3 (en) ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES
WO2006037031A3 (en) Formulations and methods for treatment of inflammatory diseases
WO2010114824A8 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
WO2007087068A3 (en) Inhibitors of tyrosine kinases and uses thereof
WO2010009892A8 (en) Compositions for the treatment of pain and/or inflamation
WO2008027557A3 (en) Topiramate compositions and methods of enhancing its bioavailability
WO2009127974A3 (en) Pharmaceutical formulation for treating cardiovascular disease
TN2009000095A1 (en) Thiazole pyrazolopyrimidines as crf1 receptor antagonists
WO2011107653A3 (en) Use of levodopa, carbidopa and entacapone for treating parkinson's disease
WO2005070462A3 (en) Compositions comprising (s)-amlodipine and an angiotensin receptor blocker and methods of their use
WO2007093450A3 (en) Deuterated catecholamine derivatives and medicaments comprising said compounds
MXPA05007857A (en) Indole-derivative modulators of steroid hormone nuclear receptors.
WO2006034373A3 (en) Variants and chemically-modified variants of phenylalanine ammonia-lyase
WO2005072045A3 (en) The combined use of glp-1 agonists and gastrin for regulating blood glucose levels
WO2006055708A3 (en) Heterocycle substituted carboxylic acids for the treatment of diabetes
WO2004099168A3 (en) Substituted carboxylic acids
NO20073774L (en) Therapeutic compounds for intranasal administration of ketorolac
TW200630327A (en) Substituted phenylalkanoic acids
EP3276004A3 (en) Methods for treating chronic kidney disease
WO2008062446A3 (en) An extended release composition of levetiracetam, which exhibits no adverse food effect
WO2008030830A3 (en) Sustained-release composition and method of use thereof
WO2007123848A3 (en) Therapeutic compositions containing modified class i slrp proteins
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
WO2007145863A3 (en) Sustained release formulation of naltrexone

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06759626

Country of ref document: EP

Kind code of ref document: A2